“Short Course” of Nonpegylated Liposomal Doxorubicin Plus Paclitaxel and Trastuzumb as Primary Systemic Therapy for Operable and Locally-Advanced Breast Cancer: A Phase II Study (PacLiDox 07)

BACKGROUND: Schedules with anthracyclines and taxanes are one of the best options for primary chemotherapy. The addition of trastuzumab showed an impressive percentage of pathological complete responses in Buzdar trial (66.7%). Recently, nonpegylated liposome-encapsulated doxorubicin (NLD) has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, D., Pistilli, B., Morale, D., Baldelli, Casadei, V., Benedetti, G., Alessandroni, P., Catalano, V., Giordani, P., Graziano, F., Fedeli, S. Luzi, Fiorentini, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649686/
https://www.ncbi.nlm.nih.gov/pubmed/29147255
http://dx.doi.org/10.4021/wjon393w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649686/
https://www.ncbi.nlm.nih.gov/pubmed/29147255
http://dx.doi.org/10.4021/wjon393w

Ejemplares similares